Dr

Ian

Brock

All publications

Journal articles

• Snowden JA, Ahmedzai SH, Cox A, Cairns DA, Ashcroft AJ, Williams C, Cavenagh JD, Hockaday A, Brown JM, Brock IW , Morris TCM et al (2022) Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study. Bone Marrow Transplantation, 57(10), 1507-1513. View this article in WRRO
• Fachal L, Aschard H, Beesley J, Barnes DR, Allen J, Kar S, Pooley KA, Dennis J, Michailidou K, Turman C , Soucy P et al (2020) Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 52(1), 56-73. View this article in WRRO
• Escala-Garcia M, Guo Q, Dörk T, Canisius S, Keeman R, Dennis J, Beesley J, Lecarpentier J, Bolla MK, Wang Q , Abraham J et al (2019) Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 120, 647-657. View this article in WRRO
• Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen T, Wang Q, Bolla MK , Yang X et al (2019) Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. The American Journal of Human Genetics, 104(1), 21-34. View this article in WRRO
• Silva S, Danson S, Teare MD, Taylor F, Bradford J, McDonagh A, Salawu A, Wells G, Burghel G, Brock I , Connley D et al (2018) Genome-wide analysis of circulating cell-free DNA copy number detects active melanoma and predicts survival . Clinical Chemistry, 64(9), 1338-1346. View this article in WRRO
• NBCS Collaborators , ABCTB Investigators & ConFab/AOCS Investigators (2017) Association analysis identifies 65 new breast cancer risk loci. Nature, 551, 92-94. View this article in WRRO
• Daniels SL, Burghel GJ, Chambers P, Al-Baba S, Connley D, Brock IW, Cramp HE, Dotsenko O, Wilks O, Wyld L , Cross SS et al (2016) Levels of DNA methylation vary at CpG sites across the BRCA1 promoter, and differ according to triple negative and "BRCA-like" status, in both blood and tumour DNA. PLoS One. View this article in WRRO
• Camp NJ, Lin WY, Bigelow A, Burghel GJ, Mosbruger T, Parry M, Waller RG, Rigas SH, Tai PY, Berrett K , Rajamanickam V et al (2016) Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus.. Cancer Research, 76(7), 1916-1925. View this article in WRRO
• Howat WJ, Blows FM, Provenzano E, Brook MN, Morris L, Gazinska P, Johnson N, McDuffus LA, Miller J, Sawyer EJ , Pinder S et al (2015) Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium.. Journal of Pathology: Clinical Research, 1(1), 18-32. View this article in WRRO
• Agarwal D, Pineda S, Michailidou K, Herranz J, Pita G, Moreno LT, Alonso MR, Dennis J, Wang Q, Bolla MK , Meyer KB et al (2014) FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. British Journal of Cancer, 110(4), 1088-1100. View this article in WRRO
• Milne RL, Herranz J, Michailidou K, Dennis J, Tyrer JP, Zamora MP, Arias-Perez JI, González-Neira A, Pita G, Alonso MR , Wang Q et al (2014) A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium. Human Molecular Genetics, 23(7), 1934-1946.
• Burghel GJ, Lin W-Y, Whitehouse H, Brock I, Hammond D, Bury J, Stephenson Y, George R & Cox A (2013) Identification of Candidate Driver Genes in Common Focal Chromosomal Aberrations of Microsatellite Stable Colorectal Cancer. PLOS ONE, 8(12). View this article in WRRO
• Mortiboys H, Cox A, Brock IW & Bandmann O (2013) The common PARK8 mutation LRRK2 G2019S is not a risk factor for breast cancer in the absence of Parkinson’s disease. Journal of Neurology, 260(8), 2177-2178.
• Lin W-Y, Brock IW, Connley D, Cramp H, Tucker R, Slate J, Reed MWR, Balasubramanian SP, Cannon-Albright LA, Camp NJ & Cox A (2013) Associations of ATR and CHEK1 Single Nucleotide Polymorphisms with Breast Cancer. PLoS ONE, 8(7). View this article in WRRO
• Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, Schmidt MK, Chang-Claude J, Bojesen SE, Bolla MK , Wang Q et al (2013) Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 45(4), 353-361.
• Daniels S, Brock I, Connley D, Cramp H, Cross S, Reed M, Wyld L & Cox A (2012) 1. Hypermethylation of distinct CpG islands within the BRCA1 promoter is associated with triple negative phenotype breast cancer. European Journal of Surgical Oncology (EJSO), 38(11), 1134-1134.
• Searle CJ, Brock IW, Cross SS, Balasubramanian SP, Reed MWR & Cox A (2012) A BCL2 promoter polymorphism rs2279115 is not associated with BCL2 protein expression or patient survival in breast cancer patients. SpringerPlus , 1. View this article in WRRO
• Kirchhoff T, Gaudet MM, Antoniou AC, McGuffog L, Humphreys MK, Dunning AM, Bojesen SE, Nordestgaard BG, Flyger H, Kang D , Yoo K-Y et al (2012) Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS ONE, 7(6). View this article in WRRO
• Lambrechts D, Truong T, Justenhoven C, Humphreys MK, Wang J, Hopper JL, Dite GS, Apicella C, Southey MC, Schmidt MK , Broeks A et al (2012) 11q13 is a susceptibility locus for hormone receptor positive breast cancer. Human Mutation, 33(7), 1123-1132.
• Milne RL, Goode EL, García-Closas M, Couch FJ, Severi G, Hein R, Fredericksen Z, Malats N, Zamora MP, Pérez JIA , Benítez J et al (2011) Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor–Positive, Lower Grade Breast Cancer. Cancer Epidemiology, Biomarkers & Prevention, 20(10), 2222-2231.
• Milne RL, Lorenzo-Bermejo J, Burwinkel B, Malats N, Arias JI, Zamora MP, Benitez J, Humphreys MK, Garcia-Closas M, Chanock SJ , Lissowska J et al (2011) 7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium. Journal of Medical Genetics, 48(10), 698-702.
• Fletcher O, Johnson N, dos Santos Silva I, Orr N, Ashworth A, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Burwinkel B , Bartram CR et al (2010) Missense Variants in ATM in 26,101 Breast Cancer Cases and 29,842 Controls. Cancer Epidemiology, Biomarkers & Prevention, 19(9), 2143-2151.
• Azzato EM, Tyrer J, Fasching PA, Beckmann MW, Ekici AB, Schulz-Wendtland R, Bojesen SE, Nordestgaard BG, Flyger H, Milne RL , Arias JI et al (2010) Association Between a Germline OCA2 Polymorphism at Chromosome 15q13.1 and Estrogen Receptor–Negative Breast Cancer Survival. JNCI: Journal of the National Cancer Institute, 102(9), 650-662.
• Milne RL, Benítez J, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Arias JI, Zamora MP, Burwinkel B, Bartram CR , Meindl A et al (2009) Risk of Estrogen Receptor–Positive and –Negative Breast Cancer and Single–Nucleotide Polymorphism 2q35-rs13387042. JNCI: Journal of the National Cancer Institute, 101(14), 1012-1018.
• Shephard ND, Abo R, Rigas SH, Frank B, Lin W-Y, Brock IW, Shippen A, Balasubramanian SP, Reed MWR, Bartram CR , Meindl A et al (2009) A Breast Cancer Risk Haplotype in the Caspase-8 Gene. Cancer Research, 69(7), 2724-2728.
• Easton DF, Pooley KA, Dunning AM, Pharoah PDP, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H & Luben R (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. NATURE, 447(7148), 1087-1093.
• Carroll T, Maltby E, Brock I, Royds J, Timperley W & Jellinek D (1999) Meningiomas, dicentric chromosomes, gliomas, and telomerase activity. The Journal of Pathology, 188(4), 395-399.
• Stevens KN, Garcia-Closas M, Fredericksen Z, Kosel M, Pankratz VS, Hopper JL, Dite GS, Apicella C, Southey MC, Schmidt MK , Broeks A et al () Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk. British Journal of Cancer, 105, 1934-1939. View this article in WRRO

Conference proceedings

• Silva S, Cox A, Teare D, Bradford J, Brock I, Connley D, Jarratt E, Parker M, Cramp H & Danson S (2018) Copy-number profiles from circulating cell-free DNA as a potential biomarker in melanoma. European Journal of Surgical Oncology, Vol. 44 (pp S26-S27)
• Silva S, Cox A, Teare D, Bradford J, Brock I, Connley D, Jarratt E, Parker M, Cramp H & Danson S (2017) Copy-number profiles from circulating cell-free DNA as a potential biomarker in melanoma. European Journal of Surgical Oncology, Vol. 43(11) (pp 2225-2225)
• Silva S, Teare D, Bradford J, Brock I, Connley D, Jarratt E, Cramp H, Taylor F, Cox A & Danson S (2016) Circulating cell-free DNA copy-number profiles as a biomarker in melanoma. European Journal of Surgical Oncology (EJSO), Vol. 42(11) (pp S245-S245)
• Shephard N, Brock I, Camp N, Canon-Albright L, Frank B, Burwinkel B & Cox A (2008) Multicentre study of CASP8 polymorphisms in breast cancer. Breast Cancer Research, Vol. 10(Suppl ) (pp P51). London, UK View this article in WRRO